nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—MT3—lung cancer	0.349	0.696	CbGaD
Prazosin—ABCG2—lung cancer	0.0692	0.138	CbGaD
Prazosin—CYP1A1—lung cancer	0.0542	0.108	CbGaD
Prazosin—ORM1—Gefitinib—lung cancer	0.0378	0.102	CbGbCtD
Prazosin—ABCB1—lung cancer	0.0288	0.0575	CbGaD
Prazosin—SLC22A3—Irinotecan—lung cancer	0.0282	0.0764	CbGbCtD
Prazosin—ABCG2—Topotecan—lung cancer	0.0252	0.0684	CbGbCtD
Prazosin—ABCG2—Gefitinib—lung cancer	0.023	0.0625	CbGbCtD
Prazosin—ABCG2—Teniposide—lung cancer	0.0223	0.0606	CbGbCtD
Prazosin—ORM1—Erlotinib—lung cancer	0.0223	0.0606	CbGbCtD
Prazosin—CYP1A1—Gefitinib—lung cancer	0.0213	0.0577	CbGbCtD
Prazosin—SLC22A2—Vinblastine—lung cancer	0.0148	0.0402	CbGbCtD
Prazosin—ABCG2—Erlotinib—lung cancer	0.0136	0.037	CbGbCtD
Prazosin—SLC22A2—Cisplatin—lung cancer	0.0136	0.0369	CbGbCtD
Prazosin—CYP1A1—Erlotinib—lung cancer	0.0126	0.0341	CbGbCtD
Prazosin—ABCG2—Paclitaxel—lung cancer	0.0125	0.0339	CbGbCtD
Prazosin—ABCG2—Irinotecan—lung cancer	0.0123	0.0334	CbGbCtD
Prazosin—ABCG2—Cisplatin—lung cancer	0.01	0.0272	CbGbCtD
Prazosin—ABCG2—Etoposide—lung cancer	0.00985	0.0267	CbGbCtD
Prazosin—ABCB1—Topotecan—lung cancer	0.00908	0.0247	CbGbCtD
Prazosin—ABCG2—Docetaxel—lung cancer	0.00902	0.0245	CbGbCtD
Prazosin—ABCB1—Gefitinib—lung cancer	0.00831	0.0226	CbGbCtD
Prazosin—ABCG2—Doxorubicin—lung cancer	0.00672	0.0182	CbGbCtD
Prazosin—ABCG2—Methotrexate—lung cancer	0.00651	0.0177	CbGbCtD
Prazosin—ABCB1—Vinorelbine—lung cancer	0.0064	0.0174	CbGbCtD
Prazosin—ABCB1—Crizotinib—lung cancer	0.00509	0.0138	CbGbCtD
Prazosin—ABCB1—Gemcitabine—lung cancer	0.00498	0.0135	CbGbCtD
Prazosin—ABCB1—Erlotinib—lung cancer	0.00491	0.0133	CbGbCtD
Prazosin—ABCB1—Paclitaxel—lung cancer	0.0045	0.0122	CbGbCtD
Prazosin—ABCB1—Irinotecan—lung cancer	0.00444	0.012	CbGbCtD
Prazosin—ABCB1—Vinblastine—lung cancer	0.00394	0.0107	CbGbCtD
Prazosin—ABCB1—Cisplatin—lung cancer	0.00362	0.00982	CbGbCtD
Prazosin—ABCB1—Etoposide—lung cancer	0.00355	0.00964	CbGbCtD
Prazosin—ABCB1—Docetaxel—lung cancer	0.00325	0.00882	CbGbCtD
Prazosin—ABCB1—Doxorubicin—lung cancer	0.00242	0.00658	CbGbCtD
Prazosin—ABCB1—Methotrexate—lung cancer	0.00235	0.00637	CbGbCtD
Prazosin—Terazosin—ABCB1—lung cancer	0.000246	0.573	CrCbGaD
Prazosin—Doxazosin—ABCB1—lung cancer	0.000183	0.427	CrCbGaD
Prazosin—Vision blurred—Paclitaxel—lung cancer	0.000126	0.00184	CcSEcCtD
Prazosin—Hyperhidrosis—Gemcitabine—lung cancer	0.000126	0.00184	CcSEcCtD
Prazosin—Dizziness—Topotecan—lung cancer	0.000125	0.00183	CcSEcCtD
Prazosin—Discomfort—Cisplatin—lung cancer	0.000125	0.00183	CcSEcCtD
Prazosin—Vomiting—Vinblastine—lung cancer	0.000124	0.00181	CcSEcCtD
Prazosin—Dizziness—Erlotinib—lung cancer	0.000124	0.00181	CcSEcCtD
Prazosin—Ill-defined disorder—Paclitaxel—lung cancer	0.000124	0.00181	CcSEcCtD
Prazosin—Malaise—Etoposide—lung cancer	0.000123	0.0018	CcSEcCtD
Prazosin—Vertigo—Etoposide—lung cancer	0.000122	0.00179	CcSEcCtD
Prazosin—Headache—Vinblastine—lung cancer	0.000122	0.00179	CcSEcCtD
Prazosin—Oedema—Cisplatin—lung cancer	0.000121	0.00178	CcSEcCtD
Prazosin—Insomnia—Irinotecan—lung cancer	0.000121	0.00177	CcSEcCtD
Prazosin—Flushing—Docetaxel—lung cancer	0.000121	0.00177	CcSEcCtD
Prazosin—Vomiting—Topotecan—lung cancer	0.00012	0.00176	CcSEcCtD
Prazosin—Malaise—Paclitaxel—lung cancer	0.00012	0.00176	CcSEcCtD
Prazosin—Paraesthesia—Irinotecan—lung cancer	0.00012	0.00176	CcSEcCtD
Prazosin—Vertigo—Paclitaxel—lung cancer	0.00012	0.00176	CcSEcCtD
Prazosin—Syncope—Paclitaxel—lung cancer	0.00012	0.00175	CcSEcCtD
Prazosin—Loss of consciousness—Etoposide—lung cancer	0.00012	0.00175	CcSEcCtD
Prazosin—Rash—Topotecan—lung cancer	0.000119	0.00175	CcSEcCtD
Prazosin—Hypersensitivity—Vinorelbine—lung cancer	0.000119	0.00175	CcSEcCtD
Prazosin—Dermatitis—Topotecan—lung cancer	0.000119	0.00175	CcSEcCtD
Prazosin—Vomiting—Erlotinib—lung cancer	0.000119	0.00174	CcSEcCtD
Prazosin—Dyspnoea—Irinotecan—lung cancer	0.000119	0.00174	CcSEcCtD
Prazosin—Somnolence—Irinotecan—lung cancer	0.000119	0.00174	CcSEcCtD
Prazosin—Headache—Topotecan—lung cancer	0.000119	0.00174	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000119	0.00174	CcSEcCtD
Prazosin—Tachycardia—Cisplatin—lung cancer	0.000118	0.00173	CcSEcCtD
Prazosin—Rash—Erlotinib—lung cancer	0.000118	0.00173	CcSEcCtD
Prazosin—Dermatitis—Erlotinib—lung cancer	0.000118	0.00173	CcSEcCtD
Prazosin—Palpitations—Paclitaxel—lung cancer	0.000118	0.00173	CcSEcCtD
Prazosin—Insomnia—Gemcitabine—lung cancer	0.000118	0.00172	CcSEcCtD
Prazosin—Headache—Erlotinib—lung cancer	0.000117	0.00172	CcSEcCtD
Prazosin—Loss of consciousness—Paclitaxel—lung cancer	0.000117	0.00172	CcSEcCtD
Prazosin—Hyperhidrosis—Cisplatin—lung cancer	0.000117	0.00172	CcSEcCtD
Prazosin—Paraesthesia—Gemcitabine—lung cancer	0.000117	0.00171	CcSEcCtD
Prazosin—Asthenia—Vinorelbine—lung cancer	0.000116	0.0017	CcSEcCtD
Prazosin—Dyspnoea—Gemcitabine—lung cancer	0.000116	0.0017	CcSEcCtD
Prazosin—Nausea—Vinblastine—lung cancer	0.000116	0.00169	CcSEcCtD
Prazosin—Somnolence—Gemcitabine—lung cancer	0.000116	0.00169	CcSEcCtD
Prazosin—Fatigue—Irinotecan—lung cancer	0.000115	0.00169	CcSEcCtD
Prazosin—Alopecia—Docetaxel—lung cancer	0.000115	0.00168	CcSEcCtD
Prazosin—Pancreatitis—Methotrexate—lung cancer	0.000115	0.00168	CcSEcCtD
Prazosin—Pruritus—Vinorelbine—lung cancer	0.000115	0.00168	CcSEcCtD
Prazosin—Discomfort—Etoposide—lung cancer	0.000114	0.00168	CcSEcCtD
Prazosin—Pain—Irinotecan—lung cancer	0.000114	0.00167	CcSEcCtD
Prazosin—Constipation—Irinotecan—lung cancer	0.000114	0.00167	CcSEcCtD
Prazosin—Arthralgia—Paclitaxel—lung cancer	0.000114	0.00166	CcSEcCtD
Prazosin—Nausea—Topotecan—lung cancer	0.000112	0.00165	CcSEcCtD
Prazosin—Discomfort—Paclitaxel—lung cancer	0.000112	0.00164	CcSEcCtD
Prazosin—Abdominal discomfort—Methotrexate—lung cancer	0.000112	0.00164	CcSEcCtD
Prazosin—Fatigue—Gemcitabine—lung cancer	0.000112	0.00164	CcSEcCtD
Prazosin—Constipation—Gemcitabine—lung cancer	0.000111	0.00163	CcSEcCtD
Prazosin—Pain—Gemcitabine—lung cancer	0.000111	0.00163	CcSEcCtD
Prazosin—Nausea—Erlotinib—lung cancer	0.000111	0.00163	CcSEcCtD
Prazosin—Dry mouth—Paclitaxel—lung cancer	0.000111	0.00163	CcSEcCtD
Prazosin—Diarrhoea—Vinorelbine—lung cancer	0.000111	0.00162	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Cisplatin—lung cancer	0.00011	0.00162	CcSEcCtD
Prazosin—Feeling abnormal—Irinotecan—lung cancer	0.00011	0.00161	CcSEcCtD
Prazosin—Oedema—Paclitaxel—lung cancer	0.000109	0.00159	CcSEcCtD
Prazosin—Paraesthesia—Cisplatin—lung cancer	0.000109	0.00159	CcSEcCtD
Prazosin—Tachycardia—Etoposide—lung cancer	0.000108	0.00159	CcSEcCtD
Prazosin—Dyspnoea—Cisplatin—lung cancer	0.000108	0.00158	CcSEcCtD
Prazosin—Erectile dysfunction—Methotrexate—lung cancer	0.000108	0.00158	CcSEcCtD
Prazosin—Hyperhidrosis—Etoposide—lung cancer	0.000107	0.00157	CcSEcCtD
Prazosin—Feeling abnormal—Gemcitabine—lung cancer	0.000107	0.00157	CcSEcCtD
Prazosin—Shock—Paclitaxel—lung cancer	0.000107	0.00157	CcSEcCtD
Prazosin—Dizziness—Vinorelbine—lung cancer	0.000107	0.00157	CcSEcCtD
Prazosin—Orthostatic hypotension—Doxorubicin—lung cancer	0.000107	0.00157	CcSEcCtD
Prazosin—Tachycardia—Paclitaxel—lung cancer	0.000106	0.00156	CcSEcCtD
Prazosin—Body temperature increased—Irinotecan—lung cancer	0.000106	0.00155	CcSEcCtD
Prazosin—Hyperhidrosis—Paclitaxel—lung cancer	0.000105	0.00154	CcSEcCtD
Prazosin—Drowsiness—Methotrexate—lung cancer	0.000104	0.00153	CcSEcCtD
Prazosin—Pain—Cisplatin—lung cancer	0.000104	0.00152	CcSEcCtD
Prazosin—Vomiting—Vinorelbine—lung cancer	0.000103	0.00151	CcSEcCtD
Prazosin—Body temperature increased—Gemcitabine—lung cancer	0.000103	0.00151	CcSEcCtD
Prazosin—Rash—Vinorelbine—lung cancer	0.000102	0.00149	CcSEcCtD
Prazosin—Dermatitis—Vinorelbine—lung cancer	0.000102	0.00149	CcSEcCtD
Prazosin—Headache—Vinorelbine—lung cancer	0.000101	0.00149	CcSEcCtD
Prazosin—Syncope—Docetaxel—lung cancer	0.000101	0.00149	CcSEcCtD
Prazosin—Palpitations—Docetaxel—lung cancer	0.0001	0.00146	CcSEcCtD
Prazosin—Feeling abnormal—Cisplatin—lung cancer	9.99e-05	0.00146	CcSEcCtD
Prazosin—Paraesthesia—Etoposide—lung cancer	9.97e-05	0.00146	CcSEcCtD
Prazosin—Loss of consciousness—Docetaxel—lung cancer	9.94e-05	0.00146	CcSEcCtD
Prazosin—Pancreatitis—Doxorubicin—lung cancer	9.93e-05	0.00145	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Paclitaxel—lung cancer	9.92e-05	0.00145	CcSEcCtD
Prazosin—Dyspnoea—Etoposide—lung cancer	9.9e-05	0.00145	CcSEcCtD
Prazosin—Somnolence—Etoposide—lung cancer	9.88e-05	0.00145	CcSEcCtD
Prazosin—Angina pectoris—Doxorubicin—lung cancer	9.87e-05	0.00144	CcSEcCtD
Prazosin—Insomnia—Paclitaxel—lung cancer	9.85e-05	0.00144	CcSEcCtD
Prazosin—Epistaxis—Methotrexate—lung cancer	9.84e-05	0.00144	CcSEcCtD
Prazosin—Hypersensitivity—Irinotecan—lung cancer	9.84e-05	0.00144	CcSEcCtD
Prazosin—Paraesthesia—Paclitaxel—lung cancer	9.78e-05	0.00143	CcSEcCtD
Prazosin—Dyspnoea—Paclitaxel—lung cancer	9.71e-05	0.00142	CcSEcCtD
Prazosin—Somnolence—Paclitaxel—lung cancer	9.68e-05	0.00142	CcSEcCtD
Prazosin—Arthralgia—Docetaxel—lung cancer	9.63e-05	0.00141	CcSEcCtD
Prazosin—Nausea—Vinorelbine—lung cancer	9.62e-05	0.00141	CcSEcCtD
Prazosin—Body temperature increased—Cisplatin—lung cancer	9.59e-05	0.0014	CcSEcCtD
Prazosin—Asthenia—Irinotecan—lung cancer	9.58e-05	0.0014	CcSEcCtD
Prazosin—Fatigue—Etoposide—lung cancer	9.58e-05	0.0014	CcSEcCtD
Prazosin—Constipation—Etoposide—lung cancer	9.5e-05	0.00139	CcSEcCtD
Prazosin—Pain—Etoposide—lung cancer	9.5e-05	0.00139	CcSEcCtD
Prazosin—Dry mouth—Docetaxel—lung cancer	9.42e-05	0.00138	CcSEcCtD
Prazosin—Fatigue—Paclitaxel—lung cancer	9.39e-05	0.00137	CcSEcCtD
Prazosin—Pollakiuria—Doxorubicin—lung cancer	9.36e-05	0.00137	CcSEcCtD
Prazosin—Asthenia—Gemcitabine—lung cancer	9.33e-05	0.00137	CcSEcCtD
Prazosin—Pain—Paclitaxel—lung cancer	9.31e-05	0.00136	CcSEcCtD
Prazosin—Constipation—Paclitaxel—lung cancer	9.31e-05	0.00136	CcSEcCtD
Prazosin—Oedema—Docetaxel—lung cancer	9.23e-05	0.00135	CcSEcCtD
Prazosin—Pruritus—Gemcitabine—lung cancer	9.2e-05	0.00135	CcSEcCtD
Prazosin—Feeling abnormal—Etoposide—lung cancer	9.15e-05	0.00134	CcSEcCtD
Prazosin—Diarrhoea—Irinotecan—lung cancer	9.14e-05	0.00134	CcSEcCtD
Prazosin—Shock—Docetaxel—lung cancer	9.08e-05	0.00133	CcSEcCtD
Prazosin—Drowsiness—Doxorubicin—lung cancer	9.03e-05	0.00132	CcSEcCtD
Prazosin—Tachycardia—Docetaxel—lung cancer	9.01e-05	0.00132	CcSEcCtD
Prazosin—Feeling abnormal—Paclitaxel—lung cancer	8.98e-05	0.00131	CcSEcCtD
Prazosin—Hypersensitivity—Cisplatin—lung cancer	8.93e-05	0.00131	CcSEcCtD
Prazosin—Diarrhoea—Gemcitabine—lung cancer	8.9e-05	0.0013	CcSEcCtD
Prazosin—Dizziness—Irinotecan—lung cancer	8.83e-05	0.00129	CcSEcCtD
Prazosin—Urticaria—Etoposide—lung cancer	8.82e-05	0.00129	CcSEcCtD
Prazosin—Body temperature increased—Etoposide—lung cancer	8.78e-05	0.00129	CcSEcCtD
Prazosin—Tinnitus—Methotrexate—lung cancer	8.73e-05	0.00128	CcSEcCtD
Prazosin—Asthenia—Cisplatin—lung cancer	8.7e-05	0.00127	CcSEcCtD
Prazosin—Urticaria—Paclitaxel—lung cancer	8.65e-05	0.00127	CcSEcCtD
Prazosin—Body temperature increased—Paclitaxel—lung cancer	8.61e-05	0.00126	CcSEcCtD
Prazosin—Epistaxis—Doxorubicin—lung cancer	8.52e-05	0.00125	CcSEcCtD
Prazosin—Vomiting—Irinotecan—lung cancer	8.49e-05	0.00124	CcSEcCtD
Prazosin—Rash—Irinotecan—lung cancer	8.42e-05	0.00123	CcSEcCtD
Prazosin—Dermatitis—Irinotecan—lung cancer	8.41e-05	0.00123	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Docetaxel—lung cancer	8.41e-05	0.00123	CcSEcCtD
Prazosin—Headache—Irinotecan—lung cancer	8.37e-05	0.00122	CcSEcCtD
Prazosin—Insomnia—Docetaxel—lung cancer	8.35e-05	0.00122	CcSEcCtD
Prazosin—Diarrhoea—Cisplatin—lung cancer	8.3e-05	0.00121	CcSEcCtD
Prazosin—Paraesthesia—Docetaxel—lung cancer	8.29e-05	0.00121	CcSEcCtD
Prazosin—Alopecia—Methotrexate—lung cancer	8.28e-05	0.00121	CcSEcCtD
Prazosin—Vomiting—Gemcitabine—lung cancer	8.27e-05	0.00121	CcSEcCtD
Prazosin—Bradycardia—Doxorubicin—lung cancer	8.26e-05	0.00121	CcSEcCtD
Prazosin—Dyspnoea—Docetaxel—lung cancer	8.23e-05	0.00121	CcSEcCtD
Prazosin—Somnolence—Docetaxel—lung cancer	8.21e-05	0.0012	CcSEcCtD
Prazosin—Rash—Gemcitabine—lung cancer	8.2e-05	0.0012	CcSEcCtD
Prazosin—Dermatitis—Gemcitabine—lung cancer	8.19e-05	0.0012	CcSEcCtD
Prazosin—Hypersensitivity—Etoposide—lung cancer	8.18e-05	0.0012	CcSEcCtD
Prazosin—Headache—Gemcitabine—lung cancer	8.15e-05	0.00119	CcSEcCtD
Prazosin—Hypersensitivity—Paclitaxel—lung cancer	8.02e-05	0.00117	CcSEcCtD
Prazosin—Asthenia—Etoposide—lung cancer	7.97e-05	0.00117	CcSEcCtD
Prazosin—Fatigue—Docetaxel—lung cancer	7.96e-05	0.00117	CcSEcCtD
Prazosin—Nausea—Irinotecan—lung cancer	7.93e-05	0.00116	CcSEcCtD
Prazosin—Constipation—Docetaxel—lung cancer	7.89e-05	0.00116	CcSEcCtD
Prazosin—Pain—Docetaxel—lung cancer	7.89e-05	0.00116	CcSEcCtD
Prazosin—Pruritus—Etoposide—lung cancer	7.86e-05	0.00115	CcSEcCtD
Prazosin—Asthenia—Paclitaxel—lung cancer	7.81e-05	0.00114	CcSEcCtD
Prazosin—Nausea—Gemcitabine—lung cancer	7.73e-05	0.00113	CcSEcCtD
Prazosin—Vomiting—Cisplatin—lung cancer	7.71e-05	0.00113	CcSEcCtD
Prazosin—Pruritus—Paclitaxel—lung cancer	7.71e-05	0.00113	CcSEcCtD
Prazosin—Vision blurred—Methotrexate—lung cancer	7.68e-05	0.00112	CcSEcCtD
Prazosin—Rash—Cisplatin—lung cancer	7.65e-05	0.00112	CcSEcCtD
Prazosin—Dermatitis—Cisplatin—lung cancer	7.64e-05	0.00112	CcSEcCtD
Prazosin—Feeling abnormal—Docetaxel—lung cancer	7.61e-05	0.00111	CcSEcCtD
Prazosin—Diarrhoea—Etoposide—lung cancer	7.6e-05	0.00111	CcSEcCtD
Prazosin—Ill-defined disorder—Methotrexate—lung cancer	7.56e-05	0.00111	CcSEcCtD
Prazosin—Tinnitus—Doxorubicin—lung cancer	7.56e-05	0.00111	CcSEcCtD
Prazosin—Flushing—Doxorubicin—lung cancer	7.53e-05	0.0011	CcSEcCtD
Prazosin—Diarrhoea—Paclitaxel—lung cancer	7.45e-05	0.00109	CcSEcCtD
Prazosin—Malaise—Methotrexate—lung cancer	7.35e-05	0.00108	CcSEcCtD
Prazosin—Dizziness—Etoposide—lung cancer	7.35e-05	0.00108	CcSEcCtD
Prazosin—Vertigo—Methotrexate—lung cancer	7.32e-05	0.00107	CcSEcCtD
Prazosin—Body temperature increased—Docetaxel—lung cancer	7.3e-05	0.00107	CcSEcCtD
Prazosin—Dizziness—Paclitaxel—lung cancer	7.2e-05	0.00105	CcSEcCtD
Prazosin—Nausea—Cisplatin—lung cancer	7.2e-05	0.00105	CcSEcCtD
Prazosin—Alopecia—Doxorubicin—lung cancer	7.17e-05	0.00105	CcSEcCtD
Prazosin—Vomiting—Etoposide—lung cancer	7.06e-05	0.00103	CcSEcCtD
Prazosin—Rash—Etoposide—lung cancer	7e-05	0.00103	CcSEcCtD
Prazosin—Dermatitis—Etoposide—lung cancer	7e-05	0.00102	CcSEcCtD
Prazosin—Headache—Etoposide—lung cancer	6.96e-05	0.00102	CcSEcCtD
Prazosin—Arthralgia—Methotrexate—lung cancer	6.94e-05	0.00102	CcSEcCtD
Prazosin—Tension—Doxorubicin—lung cancer	6.93e-05	0.00101	CcSEcCtD
Prazosin—Vomiting—Paclitaxel—lung cancer	6.93e-05	0.00101	CcSEcCtD
Prazosin—Rash—Paclitaxel—lung cancer	6.87e-05	0.00101	CcSEcCtD
Prazosin—Dermatitis—Paclitaxel—lung cancer	6.86e-05	0.001	CcSEcCtD
Prazosin—Discomfort—Methotrexate—lung cancer	6.86e-05	0.001	CcSEcCtD
Prazosin—Nervousness—Doxorubicin—lung cancer	6.86e-05	0.001	CcSEcCtD
Prazosin—Headache—Paclitaxel—lung cancer	6.82e-05	0.000999	CcSEcCtD
Prazosin—Hypersensitivity—Docetaxel—lung cancer	6.8e-05	0.000996	CcSEcCtD
Prazosin—Vision blurred—Doxorubicin—lung cancer	6.65e-05	0.000974	CcSEcCtD
Prazosin—Asthenia—Docetaxel—lung cancer	6.62e-05	0.00097	CcSEcCtD
Prazosin—Nausea—Etoposide—lung cancer	6.6e-05	0.000966	CcSEcCtD
Prazosin—Ill-defined disorder—Doxorubicin—lung cancer	6.55e-05	0.000959	CcSEcCtD
Prazosin—Pruritus—Docetaxel—lung cancer	6.53e-05	0.000956	CcSEcCtD
Prazosin—Nausea—Paclitaxel—lung cancer	6.47e-05	0.000947	CcSEcCtD
Prazosin—Hyperhidrosis—Methotrexate—lung cancer	6.43e-05	0.000942	CcSEcCtD
Prazosin—Malaise—Doxorubicin—lung cancer	6.37e-05	0.000932	CcSEcCtD
Prazosin—Vertigo—Doxorubicin—lung cancer	6.34e-05	0.000929	CcSEcCtD
Prazosin—Syncope—Doxorubicin—lung cancer	6.33e-05	0.000927	CcSEcCtD
Prazosin—Diarrhoea—Docetaxel—lung cancer	6.32e-05	0.000925	CcSEcCtD
Prazosin—Palpitations—Doxorubicin—lung cancer	6.24e-05	0.000913	CcSEcCtD
Prazosin—Loss of consciousness—Doxorubicin—lung cancer	6.2e-05	0.000908	CcSEcCtD
Prazosin—Dizziness—Docetaxel—lung cancer	6.1e-05	0.000894	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Methotrexate—lung cancer	6.06e-05	0.000888	CcSEcCtD
Prazosin—Insomnia—Methotrexate—lung cancer	6.02e-05	0.000881	CcSEcCtD
Prazosin—Arthralgia—Doxorubicin—lung cancer	6.01e-05	0.00088	CcSEcCtD
Prazosin—Paraesthesia—Methotrexate—lung cancer	5.97e-05	0.000875	CcSEcCtD
Prazosin—Discomfort—Doxorubicin—lung cancer	5.94e-05	0.000869	CcSEcCtD
Prazosin—Dyspnoea—Methotrexate—lung cancer	5.93e-05	0.000869	CcSEcCtD
Prazosin—Somnolence—Methotrexate—lung cancer	5.92e-05	0.000866	CcSEcCtD
Prazosin—Dry mouth—Doxorubicin—lung cancer	5.88e-05	0.000861	CcSEcCtD
Prazosin—Vomiting—Docetaxel—lung cancer	5.87e-05	0.000859	CcSEcCtD
Prazosin—Rash—Docetaxel—lung cancer	5.82e-05	0.000852	CcSEcCtD
Prazosin—Dermatitis—Docetaxel—lung cancer	5.82e-05	0.000851	CcSEcCtD
Prazosin—Headache—Docetaxel—lung cancer	5.78e-05	0.000847	CcSEcCtD
Prazosin—Oedema—Doxorubicin—lung cancer	5.76e-05	0.000844	CcSEcCtD
Prazosin—Fatigue—Methotrexate—lung cancer	5.74e-05	0.00084	CcSEcCtD
Prazosin—Pain—Methotrexate—lung cancer	5.69e-05	0.000833	CcSEcCtD
Prazosin—Shock—Doxorubicin—lung cancer	5.67e-05	0.00083	CcSEcCtD
Prazosin—Tachycardia—Doxorubicin—lung cancer	5.62e-05	0.000823	CcSEcCtD
Prazosin—Hyperhidrosis—Doxorubicin—lung cancer	5.57e-05	0.000815	CcSEcCtD
Prazosin—Nausea—Docetaxel—lung cancer	5.48e-05	0.000803	CcSEcCtD
Prazosin—Feeling abnormal—Methotrexate—lung cancer	5.48e-05	0.000803	CcSEcCtD
Prazosin—Urticaria—Methotrexate—lung cancer	5.29e-05	0.000774	CcSEcCtD
Prazosin—Body temperature increased—Methotrexate—lung cancer	5.26e-05	0.00077	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Doxorubicin—lung cancer	5.25e-05	0.000769	CcSEcCtD
Prazosin—Insomnia—Doxorubicin—lung cancer	5.21e-05	0.000763	CcSEcCtD
Prazosin—Paraesthesia—Doxorubicin—lung cancer	5.17e-05	0.000757	CcSEcCtD
Prazosin—Dyspnoea—Doxorubicin—lung cancer	5.14e-05	0.000752	CcSEcCtD
Prazosin—Somnolence—Doxorubicin—lung cancer	5.12e-05	0.00075	CcSEcCtD
Prazosin—Fatigue—Doxorubicin—lung cancer	4.97e-05	0.000727	CcSEcCtD
Prazosin—Pain—Doxorubicin—lung cancer	4.93e-05	0.000721	CcSEcCtD
Prazosin—Constipation—Doxorubicin—lung cancer	4.93e-05	0.000721	CcSEcCtD
Prazosin—Hypersensitivity—Methotrexate—lung cancer	4.9e-05	0.000718	CcSEcCtD
Prazosin—Asthenia—Methotrexate—lung cancer	4.77e-05	0.000699	CcSEcCtD
Prazosin—Feeling abnormal—Doxorubicin—lung cancer	4.75e-05	0.000695	CcSEcCtD
Prazosin—Pruritus—Methotrexate—lung cancer	4.71e-05	0.000689	CcSEcCtD
Prazosin—Urticaria—Doxorubicin—lung cancer	4.58e-05	0.00067	CcSEcCtD
Prazosin—Body temperature increased—Doxorubicin—lung cancer	4.55e-05	0.000667	CcSEcCtD
Prazosin—Diarrhoea—Methotrexate—lung cancer	4.55e-05	0.000667	CcSEcCtD
Prazosin—Dizziness—Methotrexate—lung cancer	4.4e-05	0.000644	CcSEcCtD
Prazosin—Hypersensitivity—Doxorubicin—lung cancer	4.24e-05	0.000621	CcSEcCtD
Prazosin—Vomiting—Methotrexate—lung cancer	4.23e-05	0.000619	CcSEcCtD
Prazosin—Rash—Methotrexate—lung cancer	4.2e-05	0.000614	CcSEcCtD
Prazosin—Dermatitis—Methotrexate—lung cancer	4.19e-05	0.000614	CcSEcCtD
Prazosin—Headache—Methotrexate—lung cancer	4.17e-05	0.00061	CcSEcCtD
Prazosin—Asthenia—Doxorubicin—lung cancer	4.13e-05	0.000605	CcSEcCtD
Prazosin—Pruritus—Doxorubicin—lung cancer	4.08e-05	0.000597	CcSEcCtD
Prazosin—Nausea—Methotrexate—lung cancer	3.95e-05	0.000579	CcSEcCtD
Prazosin—Diarrhoea—Doxorubicin—lung cancer	3.94e-05	0.000577	CcSEcCtD
Prazosin—Dizziness—Doxorubicin—lung cancer	3.81e-05	0.000558	CcSEcCtD
Prazosin—Vomiting—Doxorubicin—lung cancer	3.66e-05	0.000536	CcSEcCtD
Prazosin—Rash—Doxorubicin—lung cancer	3.63e-05	0.000532	CcSEcCtD
Prazosin—Dermatitis—Doxorubicin—lung cancer	3.63e-05	0.000531	CcSEcCtD
Prazosin—Headache—Doxorubicin—lung cancer	3.61e-05	0.000528	CcSEcCtD
Prazosin—Nausea—Doxorubicin—lung cancer	3.42e-05	0.000501	CcSEcCtD
Prazosin—ADRA1A—Signaling Pathways—BRAF—lung cancer	2.36e-06	3.83e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—STAT3—lung cancer	2.36e-06	3.83e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CB—lung cancer	2.36e-06	3.83e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MTOR—lung cancer	2.36e-06	3.83e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NRAS—lung cancer	2.36e-06	3.82e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—PIK3CA—lung cancer	2.35e-06	3.81e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTEN—lung cancer	2.34e-06	3.8e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MDM2—lung cancer	2.34e-06	3.8e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCND1—lung cancer	2.34e-06	3.8e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KIT—lung cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APC—lung cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—NRAS—lung cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6R—lung cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—JUN—lung cancer	2.34e-06	3.79e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—RAF1—lung cancer	2.33e-06	3.79e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CREBBP—lung cancer	2.33e-06	3.78e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGF—lung cancer	2.31e-06	3.75e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ERBB2—lung cancer	2.31e-06	3.74e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—POMC—lung cancer	2.3e-06	3.74e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—EGFR—lung cancer	2.29e-06	3.72e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CB—lung cancer	2.28e-06	3.7e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MTOR—lung cancer	2.28e-06	3.7e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MMP9—lung cancer	2.27e-06	3.69e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CXCL8—lung cancer	2.27e-06	3.68e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CDKN1A—lung cancer	2.26e-06	3.67e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—lung cancer	2.26e-06	3.66e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—EP300—lung cancer	2.26e-06	3.66e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK3—lung cancer	2.26e-06	3.66e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—HRAS—lung cancer	2.25e-06	3.65e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—CREBBP—lung cancer	2.24e-06	3.64e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—PIK3CA—lung cancer	2.24e-06	3.63e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	2.24e-06	3.63e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—EP300—lung cancer	2.23e-06	3.62e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MDM2—lung cancer	2.23e-06	3.62e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	2.23e-06	3.61e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—POMC—lung cancer	2.22e-06	3.61e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—RAF1—lung cancer	2.22e-06	3.6e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	2.21e-06	3.59e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKT1—lung cancer	2.2e-06	3.57e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ERBB2—lung cancer	2.2e-06	3.57e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—BRAF—lung cancer	2.2e-06	3.56e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—lung cancer	2.19e-06	3.56e-05	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKT1—lung cancer	2.19e-06	3.55e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	2.19e-06	3.55e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CXCL8—lung cancer	2.19e-06	3.55e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—lung cancer	2.18e-06	3.54e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—HRAS—lung cancer	2.18e-06	3.53e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CASP3—lung cancer	2.17e-06	3.52e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6R—lung cancer	2.17e-06	3.52e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CB—lung cancer	2.17e-06	3.52e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MTOR—lung cancer	2.17e-06	3.52e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL2—lung cancer	2.17e-06	3.52e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CREBBP—lung cancer	2.17e-06	3.51e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—lung cancer	2.17e-06	3.51e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6—lung cancer	2.16e-06	3.5e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EP300—lung cancer	2.15e-06	3.49e-05	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—AKT1—lung cancer	2.15e-06	3.49e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EGFR—lung cancer	2.15e-06	3.48e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CB—lung cancer	2.14e-06	3.47e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—EGFR—lung cancer	2.13e-06	3.45e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CD—lung cancer	2.13e-06	3.45e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTGS2—lung cancer	2.12e-06	3.44e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—APOA1—lung cancer	2.12e-06	3.43e-05	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKT1—lung cancer	2.12e-06	3.43e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—lung cancer	2.11e-06	3.43e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—JUN—lung cancer	2.11e-06	3.42e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ALB—lung cancer	2.1e-06	3.41e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CASP3—lung cancer	2.1e-06	3.4e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—SRC—lung cancer	2.1e-06	3.4e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL2—lung cancer	2.09e-06	3.39e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CXCL8—lung cancer	2.09e-06	3.38e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—EP300—lung cancer	2.08e-06	3.38e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6—lung cancer	2.08e-06	3.38e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—HRAS—lung cancer	2.07e-06	3.36e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	2.07e-06	3.35e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	2.05e-06	3.33e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MMP9—lung cancer	2.05e-06	3.33e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	2.04e-06	3.32e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—lung cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—lung cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—lung cancer	2.04e-06	3.31e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—JUN—lung cancer	2.04e-06	3.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	2.04e-06	3.3e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—lung cancer	2.03e-06	3.29e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—lung cancer	2.02e-06	3.28e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NRAS—lung cancer	2.02e-06	3.27e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	2.01e-06	3.27e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—lung cancer	2.01e-06	3.26e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CASP3—lung cancer	2e-06	3.24e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL2—lung cancer	1.99e-06	3.23e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKT1—lung cancer	1.99e-06	3.23e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	1.99e-06	3.23e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6—lung cancer	1.98e-06	3.22e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MDM2—lung cancer	1.98e-06	3.21e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MMP9—lung cancer	1.98e-06	3.21e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—RAF1—lung cancer	1.97e-06	3.2e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1A—lung cancer	1.97e-06	3.2e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—lung cancer	1.97e-06	3.19e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ERBB2—lung cancer	1.95e-06	3.17e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EP300—lung cancer	1.95e-06	3.15e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—lung cancer	1.94e-06	3.15e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—JUN—lung cancer	1.94e-06	3.14e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CG—lung cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK3—lung cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MTOR—lung cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	1.93e-06	3.13e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKT1—lung cancer	1.92e-06	3.12e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—SRC—lung cancer	1.89e-06	3.07e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MMP9—lung cancer	1.89e-06	3.06e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	1.88e-06	3.05e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EP300—lung cancer	1.88e-06	3.05e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—lung cancer	1.88e-06	3.04e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—lung cancer	1.88e-06	3.04e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PIK3CA—lung cancer	1.86e-06	3.02e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CB—lung cancer	1.85e-06	3.01e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CXCL8—lung cancer	1.85e-06	3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—lung cancer	1.85e-06	3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.85e-06	3e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—lung cancer	1.84e-06	2.99e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.84e-06	2.99e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—HRAS—lung cancer	1.84e-06	2.98e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—POMC—lung cancer	1.84e-06	2.98e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTGS2—lung cancer	1.84e-06	2.98e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EGFR—lung cancer	1.84e-06	2.98e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—RAF1—lung cancer	1.83e-06	2.97e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKT1—lung cancer	1.83e-06	2.97e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—SRC—lung cancer	1.83e-06	2.96e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.82e-06	2.96e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NRAS—lung cancer	1.82e-06	2.95e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1.81e-06	2.94e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—lung cancer	1.8e-06	2.92e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CREBBP—lung cancer	1.79e-06	2.91e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MTOR—lung cancer	1.79e-06	2.9e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	1.79e-06	2.9e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	1.79e-06	2.9e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EP300—lung cancer	1.79e-06	2.9e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—lung cancer	1.78e-06	2.88e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CASP3—lung cancer	1.77e-06	2.88e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL2—lung cancer	1.77e-06	2.87e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—EP300—lung cancer	1.77e-06	2.86e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6—lung cancer	1.76e-06	2.86e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—lung cancer	1.76e-06	2.86e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NRAS—lung cancer	1.76e-06	2.85e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK3—lung cancer	1.74e-06	2.83e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—SRC—lung cancer	1.74e-06	2.82e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—lung cancer	1.73e-06	2.81e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—lung cancer	1.73e-06	2.8e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HRAS—lung cancer	1.72e-06	2.79e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—JUN—lung cancer	1.72e-06	2.79e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CXCL8—lung cancer	1.72e-06	2.79e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—HRAS—lung cancer	1.71e-06	2.77e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CD—lung cancer	1.7e-06	2.76e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—lung cancer	1.7e-06	2.75e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—lung cancer	1.69e-06	2.75e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK3—lung cancer	1.68e-06	2.73e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ALB—lung cancer	1.68e-06	2.72e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—lung cancer	1.68e-06	2.72e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MMP9—lung cancer	1.68e-06	2.72e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NRAS—lung cancer	1.67e-06	2.71e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CA—lung cancer	1.67e-06	2.71e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	1.67e-06	2.71e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—lung cancer	1.67e-06	2.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.66e-06	2.7e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.66e-06	2.69e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CA—lung cancer	1.65e-06	2.68e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6—lung cancer	1.65e-06	2.67e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.65e-06	2.67e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL2—lung cancer	1.64e-06	2.67e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.64e-06	2.65e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—lung cancer	1.64e-06	2.65e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKT1—lung cancer	1.63e-06	2.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.6e-06	2.6e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—lung cancer	1.6e-06	2.6e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK3—lung cancer	1.6e-06	2.6e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EGFR—lung cancer	1.6e-06	2.6e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—JUN—lung cancer	1.6e-06	2.59e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	1.59e-06	2.58e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EP300—lung cancer	1.59e-06	2.58e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.57e-06	2.54e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—lung cancer	1.56e-06	2.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.56e-06	2.52e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.55e-06	2.52e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.55e-06	2.51e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SRC—lung cancer	1.54e-06	2.51e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—lung cancer	1.54e-06	2.5e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CA—lung cancer	1.54e-06	2.5e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—EP300—lung cancer	1.53e-06	2.48e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGFR—lung cancer	1.52e-06	2.47e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKT1—lung cancer	1.52e-06	2.47e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—lung cancer	1.51e-06	2.45e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKT1—lung cancer	1.51e-06	2.45e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—lung cancer	1.5e-06	2.44e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—lung cancer	1.49e-06	2.42e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NRAS—lung cancer	1.49e-06	2.41e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CB—lung cancer	1.48e-06	2.4e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EP300—lung cancer	1.48e-06	2.39e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HRAS—lung cancer	1.47e-06	2.39e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTGS2—lung cancer	1.47e-06	2.38e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—lung cancer	1.44e-06	2.34e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	1.44e-06	2.33e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SRC—lung cancer	1.44e-06	2.33e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK3—lung cancer	1.42e-06	2.31e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6—lung cancer	1.41e-06	2.29e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—lung cancer	1.4e-06	2.27e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—lung cancer	1.39e-06	2.26e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CA—lung cancer	1.39e-06	2.25e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—lung cancer	1.38e-06	2.24e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—lung cancer	1.38e-06	2.24e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NRAS—lung cancer	1.38e-06	2.24e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—AKT1—lung cancer	1.36e-06	2.21e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGFR—lung cancer	1.35e-06	2.2e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—AKT1—lung cancer	1.35e-06	2.19e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—lung cancer	1.34e-06	2.18e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HRAS—lung cancer	1.33e-06	2.16e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	1.32e-06	2.15e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.32e-06	2.14e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CA—lung cancer	1.31e-06	2.12e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKT1—lung cancer	1.3e-06	2.11e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—lung cancer	1.29e-06	2.09e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HRAS—lung cancer	1.29e-06	2.08e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—lung cancer	1.28e-06	2.08e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—lung cancer	1.28e-06	2.08e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—lung cancer	1.28e-06	2.07e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6—lung cancer	1.27e-06	2.07e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—AKT1—lung cancer	1.26e-06	2.04e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.26e-06	2.04e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6—lung cancer	1.23e-06	1.99e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HRAS—lung cancer	1.22e-06	1.98e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—EP300—lung cancer	1.22e-06	1.98e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.19e-06	1.93e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKT1—lung cancer	1.18e-06	1.91e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	1.18e-06	1.91e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6—lung cancer	1.17e-06	1.9e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—lung cancer	1.14e-06	1.84e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKT1—lung cancer	1.13e-06	1.84e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CA—lung cancer	1.13e-06	1.83e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.09e-06	1.77e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HRAS—lung cancer	1.09e-06	1.76e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKT1—lung cancer	1.08e-06	1.75e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AKT1—lung cancer	1.07e-06	1.73e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—lung cancer	1.06e-06	1.71e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6—lung cancer	1.04e-06	1.69e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.01e-06	1.64e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6—lung cancer	9.67e-07	1.57e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT1—lung cancer	9.6e-07	1.56e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AKT1—lung cancer	9.23e-07	1.5e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CA—lung cancer	9.03e-07	1.46e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT1—lung cancer	8.92e-07	1.45e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AKT1—lung cancer	7.38e-07	1.2e-05	CbGpPWpGaD
